Skip to content

Dr. Lane discusses results of triplet combo in BPCDN
New therapies push UK registries into central role
FDA approves subcutaneous mosunetuzumab in relapsed or refractory follicular lymphoma
Dr. Gloria Iacoboni on improving CAR T-cell therapy outcomes in lymphoma
Q&A: Dr. Gohil on the multidisciplinary approach to HLH

Join SOHO

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Multiple Myeloma News

ISAF approves equecabtagene autoleucel for relapsed or refractory multiple myeloma

by SOHO Insider Editors
April 10, 2025
0 Comments

Cellular Therapy 2025 EBMT Annual Meeting Multiple Myeloma News

CARTITUDE-4: Nearly 75% of patients alive 3 years after cilta-cel treatment for myeloma

by SOHO Insider Editors
April 9, 2025
0 Comments

Multiple Myeloma

Dr. Lipof discusses Myeloma Action Month

by Leah Sherwood
March 30, 2025
0 Comments

Leukemia Lymphoma Multiple Myeloma News

Is it time to revisit MRD’s role in relapse detection?

by SOHO Insider Editors
March 25, 2025
0 Comments

Multiple Myeloma

China NMPA approves IND for KPG-818 in relapsed or refractory MM

by SOHO Insider Editors
March 20, 2025
0 Comments

Cellular Therapy Multiple Myeloma

Patient case highlights secondary tumor after CAR-T treatment for myeloma

by SOHO Insider Editors
March 12, 2025
0 Comments

Multiple Myeloma

Combination monoclonal antibody treatment induces responses but also infections in MM

by SOHO Insider Editors
March 5, 2025
0 Comments

Multiple Myeloma

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

by SOHO Insider Editors
March 4, 2025
0 Comments

Multiple Myeloma

FDA grants Orphan Drug Designation for small-molecule MM therapy

by SOHO Insider Editors
February 27, 2025
0 Comments

Cellular Therapy Multiple Myeloma

Real-world study observes ‘superior’ outcomes with cilta-cel versus ide-cel for myeloma

by SOHO Insider Editors
February 26, 2025
0 Comments

1
...
5
6
7
8
9

Top Categories

Cellular Therapy

57

Leukemia

93

Lymphoma

99

Multiple Myeloma

82

Myelodysplastic Syndromes

31

Myeloproliferative Neoplasms

20

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Multiple Myeloma News

ISAF approves equecabtagene autoleucel for relapsed or refractory multiple myeloma

CARTITUDE-4: Nearly 75% of patients alive 3 years after cilta-cel treatment for myeloma

Dr. Lipof discusses Myeloma Action Month

Is it time to revisit MRD’s role in relapse detection?

China NMPA approves IND for KPG-818 in relapsed or refractory MM

Patient case highlights secondary tumor after CAR-T treatment for myeloma

Combination monoclonal antibody treatment induces responses but also infections in MM

A modified quadruplet therapy is feasible for older, transplant-ineligible MM patients

FDA grants Orphan Drug Designation for small-molecule MM therapy

Real-world study observes ‘superior’ outcomes with cilta-cel versus ide-cel for myeloma

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

Dr. Lane discusses results of triplet combo in BPCDN

New therapies push UK registries into central role

FDA approves subcutaneous mosunetuzumab in relapsed or refractory follicular lymphoma

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

Multiple Myeloma News

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms